Gerald Chi
scholar.google.com
0000-0002-8371-1689
122 papers found
Refreshing results…
Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy
Effect of Intensive Versus Standard Blood Pressure Control on Stroke and Serious Adverse Event: A Bivariate Analysis on the Net Clinical Benefit
P5599 Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy
P1551 D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely Ill medical patients: insights from the APEX trial.
Abstract 20444: Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy.
Abstract 20377: Bivariate Analysis of Major Adverse Cardiac Events and Serious Adverse Events in Clinical Trials Comparing Intensive Versus Standard Blood Pressure Control Strategy.
P1732 Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy.
Effect of Low-Dose versus Very-Low-Dose Rivaroxaban on Stroke and Major Bleeding Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: A Bivariate Analysis on the Net Clinical Benefit
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial
Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis
The Association Between Left Ventricular Mass and Measures of Infarct Size in Anterior St-Segment Elevation Myocardial Infarction: Insights From the Embrace Stemi Clinical Trial
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy
The Relationship Between Patency of the Culprit Artery on Admission and Electrolyte Changes in Anterior STEMI - Analysis From the EMBRACE STEMI Clinical Trial
Abstract 19208: Extended Duration Betrixaban Reduces the Risk of Stroke vs Standard Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Substudy.
Abstract 18092: The Relationship Between Patency of the Culprit Artery on Admission and Electrolyte Changes in Anterior STEMI - Analysis From the EMBRACE STEMI Clinical Trial.
Abstract 19875: IMPROVEDD Score: Addition of D-Dimer to the IMPROVE Score Improves Venous Thromboembolism Risk Stratification. An APEX Trial Substudy.
Missing publications? Search for publications with a matching author name.